Piperine 98%

Product Name: Black Pepper extract
Latin Name: Piper nigrum L. 
Part used: Seed
Specification: Piperine 50%, 90%, 98%
Test Method: HPLC
Particle size: 80mesh
CAS No.: 94-62-2
Molecular Formula: C17H19NO3

What is pipperine:

Piperine is the alkaloid responsible for the pungency of black pepper and long pepper, along with chavicine (an isomer of piperine).Piperine is often added to prepared food to enhance aroma and flavor.It can Promote drug absorption, and improve the effectiveness of the drug function. In clinical practice, it can induce calm (sedative effect) or to induce sleep (hypnotic effect), and used to make anticonvulsant, antidepressant, and muscle relaxation drug.
 Piperine has also been found to inhibit human CYP3A4 and P-glycoprotein, enzymes important for the metabolism and transport of xenobiotics and metabolites.In animal studies, piperine also inhibited other enzymes important in drug metabolism.By inhibiting drug metabolism, piperine may increase the bioavailability of various compounds. Notably, piperine may enhance bioavailability of curcumin by 2000% in humans.


Staherb piperine main function:

1.With the function of lipid-lowering, anti-inflammatory, choleretic, anti-tumor and anti-oxidation;

2.It is a natural food coloring, having strong coloring ability, good heat resistance and light resistance.

3. Detoxication, Choleretic effect.

4. Antibacterial, anti-inflammatory.

5. Reducing blood-lipid, anti-hypertension.

6. Having the ability of termination Of pregnancy.

7.With the function of improving blood circulation and treating amenorrhea;

8.With the function of treating women's dysmenorrhea and amenorrhea.


Staherb piperine application:

1. Piperine used to treat flatulence, gout, laryngitis, and paralysis.
2. Piperine used to treat abdominal tumors and gastric ulcers.
3. Piperine improve the digestive system.
4. Piperine enhances the immune system.

For more product inforamtion pls contact email sales09@staherb.cn



  1. 1.

    Kumar R, Hafner LM, Engwerda CR. Immune regulation during chronic visceral leishmaniasis. PLoS Negl Trop Dis. 2014;8(7):e2914.

  2. 2.

    Kole L, Das L, Das PK. Synergistic effect of interferon-g and mannosylated liposome incorporated doxorubicin in the therapy of experimental visceral leishmaniasis. J Infect Dis. 1999;180:811–20.

  3. 3.

    Elizabeth M, Contreras M. Chemotherapy used in the treatment of visceral leishmaniasis. CPQ Microbiol. 2019;3(1):01–14. 

  4. 4.

    Soto J, Soto P. Miltefosine: oral treatment of leishmaniasis. Expert Rev Anti-Infect Ther. 2006;4:177–85. 

  5. 5.

    Sundar S, Chakravarty J. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. Expert Opin Investig Drugs. 2015;24:43–59. 

  6. 6.

    Paila YD, Bhaskar Saha B, Chattopadhyay A. Amphotericin B inhibits entry of Leishmania donovani into primary macrophages. Biochem Biophys Res Commun. 2010;399:429–33. 

  7. 7.

    Italia JL, Yahya MM, Singh D, Ravi Kumar MN. Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone. Pharm Res. 2009;26(6):1324–31. 

  8. 8.

    Laniado-Laborín R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Rev Iberoam Micol. 2009;26(4):223–7. 

  9. 9.

    Zaioncz S, Khalil NM, Mainardes RM. Exploring the role of nanoparticles in amphotericin B delivery. Curr Pharm Des. 2017;23(3):509–21. 

  10. 10.

    Malani PN, Depestel DD, Riddell J, Bickley S, Klein LR, Kauffman CA. Experience with community-based amphotericin B infusion therapy. Pharmacotherapy. 2005;25:690–7. 

  11. 11.

    Polonio T, Efferth T. Leishmaniasis: drug resistance and natural products. Int J Mol Med. 2008;22:277–86. 

  12. 12.

    Mishra BB, Kale RR, Singh RK, Tiwari VK. Alkaloids: future prospective to combat leishmaniasis. Fitoterapia. 2009;80:81–90. 

  13. 13.

    Wadhwa S, Singhal S, Rawat S. Bioavailability enhancement by piperine: a review. Asian J Biomed Pharm Sci. 2014;04(36):1–8.

  14. 14.

    Randhawa KG, Kullar SJ, Rajkumar. Bioenhancer from mother nature and their applicability to modern medicines. International journal of applied and basic medicinal research. Int J App Basic Med Res. 2001;1(1):5–10.


  15. 15.

    Moretton MA, Chiappetta DA, Andrade F, Das Neves J, Ferreira D, Sarmento B, et al. Hydrolyzed galactomannan-modified nanoparticles and flower-like polymeric micelles for the active targeting of rifampicin to macrophages. J Biomed Nanotechnol. 2013;9(6):1076–87. 

  16. 16.

    Bansal R, Singh A, Gandhi R, Pant AB, Kumar P, Gupta KC. Galactomannan-PEI based non-viral vectors for targeted delivery of plasmid to macrophages and hepatocytes. Eur J Pharm Biopharm. 2014;87(3):461–71.

  17. 17.

    Coviello T, Alhaique F, Dorigo A, Matricardi P, Grassi M. Two galactomannans and scleroglucan as matrices for drug delivery: preparation and release studies. Eur J Pharm Biopharm. 2007;66(2):200–9.

  18. 18.

    Nurnadiah R, Kamarun D, Li AR, Ahmad MR. Synthesis and characterization of crosslinked galactomannan nanoparticles for drug delivery application. Adv Mater Res. 2013;812:12–9. 

  19. 19.

    Duncan CJ, Pugh N, Pasco DS, Ross SA. Isolation of a galactomannan that enhances macrophage activation from the edible fungus Morchella esculenta. J Agric Food Chem. 2002;50(20):5683–5.

  20. 20.

    Y-m H, Chun S-H, S-t H, Y-c K, H-d C, Lee K-w. Immune enhancing effect of a Maillard-type lysozyme-galactomannan conjugate via signaling pathways. Int J Biol Macromol. 2013;60:399–404. 

  21. 21.

    Noleto GR, Mercê ALR, Iacomini M, Gorin PA, Soccol VT, Oliveira MBM. Effects of a lichen galactomannan and its vanadyl (IV) complex on peritoneal macrophages and leishmanicidal activity. Mol Cell Biochem. 2002;233(1–2):73–83.

  22. 22.

    Hosny KM. Alendronate sodium as enteric coated solid lipid nanoparticles; preparation, optimization, and in vivo evaluation to enhance its oral bioavailability. PlosOne. 2016;11(5):e0154926.

  23. 23.

    Ray L, Kumar P, Gupta KC. The activity against Ehrlich’s ascites tumors of doxorubicin contained in self assembled, cell receptor targeted nanoparticles with simultaneous oral delivery of the green tea polyphenol epigallocatechin-3-gallate. Biomaterials. 2013;34:3064–76.

  24. 24.

    Ray L, Pal MK, Ray RS. Synergism of co-delivered nanosized antioxidants displayed enhanced anticancer efficacy in human colon cancer cell lines. Bioact Mater. 2017;2:1–14.

  25. 25.

    Ashutosh, Gupta S, Ramesh, Sundar S, Goyal N. Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening. Antimicrob Agents Chemother. 2005;49:3776–83.

  26. 26.

    Seifert K, Croft SL. In vitro and in vivo interactions between sodium stibogluconate, miltefosine and other antileishmanial drug. Antimicrob Agents Chemother. 2006;50:73–9.

  27. 27.

    Bhatnagar S, Guru PY, Katiyar JC, Srivastava R, Mukherjee A, Akhtar MS. Exploration of antileishmanial activity in heterocycles; results of their in vivo & in vitro bioevaluations. Indian J Med Res. 1989;89:439–43.

  28. 28.

    Gershkovich P, Sivak O, Wasan EK, Magil AB, Owen D, Clement JG, et al. Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009) J. Antimicrob Chemother. 2010;65:2610–3.

  29. 29.

    Deshpande NM, Gangrade MG, Kekarea MB, Vaidya VV. Determination of free and liposomal amphotericin B in human plasma by liquid chromatography–mass spectroscopy with solid phase extraction and protein precipitation techniques. J Chromatogr B. 2010;878:315–26.

  30. 30.

    Peters JH. The determination of creatinine and creatine in blood and urine with the photoelectric colorimeter. J. biol. Chem, 1942;146: 179-186.

  31. 31.

    Katiyar SS, Muntimadugu E, Rafeeqi AT, Domb AJ, Khan W. Co-delivery of rapamycin- and piperine-loaded polymeric nanoparticles for breast cancer treatment. Drug Deliv. 2016;23:2608–16.

  32. 32.

    Fallingborg J. Intraluminal pH of the human gastrointestinal tract. Dan Med Bull. 1999;46:183–96.

  33. 33.

    Lee KW, Everts H, Beynen AC. Essential oils in broiler nutrition. Int J Poult Sci. 2004;3:738–52.

  34. 34.

    Annamalai AR, Manavlan R. Trikatu- A bioavailability enhancer. Indian Drugs. 1989;27:595–604.

  35. 35.

    Khajuria A, Thusu N, Zutshi U. Piperine modulates permeability characteristics of intestine by inducing alterations in membrane dynamics: influence on brush border membrane fluidity, ultrastructure and enzyme kinetics. Phytomedicine. 2002;9:224–31.

  36. 36.

    Reen RK, Singh J. In vitro and in vivo inhibition of pulmonary cytochrome P450 activities by piperine, a major ingredient of piper species. Indian J Exp Biol. 1991;29:568–73. 

  37. 37.

    Sobh MA, Moustafa FE, Ramzy RM, Deelder AM, Ghoneim MA. Schistosoma haematobium-induced glomerular disease: an experiment study in the golden hamster. Nephron. 1991;57:216–24.